ProKidney Corp. (NASDAQ:PROK) Receives Consensus Rating of “Moderate Buy” from Analysts

Posted by on Jun 12th, 2026

ProKidney Corp. (NASDAQ:PROK – Get Free Report) has earned an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $7.40.

PROK has been the subject of a number of research reports. Wall Street Zen lowered shares of ProKidney from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of ProKidney in a report on Monday, May 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of ProKidney in a report on Tuesday, April 21st. Finally, Jefferies Financial Group raised shares of ProKidney to a “strong-buy” rating in a report on Wednesday, March 18th.

Read Our Latest Research Report on PROK

Institutional Trading of ProKidney

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp increased its holdings in shares of ProKidney by 1.1% in the fourth quarter. State Street Corp now owns 480,345 shares of the company’s stock valued at $1,076,000 after purchasing an additional 5,388 shares in the last quarter. Squarepoint Ops LLC boosted its stake in ProKidney by 2.0% in the fourth quarter. Squarepoint Ops LLC now owns 351,421 shares of the company’s stock valued at $787,000 after acquiring an additional 6,845 shares during the last quarter. Cetera Investment Advisers bought a new position in ProKidney in the fourth quarter valued at approximately $28,000. R Squared Ltd bought a new position in ProKidney in the first quarter valued at approximately $25,000. Finally, SummitTX Capital L.P. bought a new position in ProKidney in the first quarter valued at approximately $26,000. Institutional investors and hedge funds own 51.59% of the company’s stock.

ProKidney Trading Down 0.6%

NASDAQ PROK opened at $1.66 on Friday. The firm has a market cap of $501.42 million, a price-to-earnings ratio of -3.13 and a beta of 1.64. The company has a 50 day moving average of $1.84 and a 200-day moving average of $2.06. ProKidney has a 1-year low of $0.54 and a 1-year high of $7.13.

ProKidney (NASDAQ:PROK – Get Free Report) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The firm had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.10 million. On average, analysts forecast that ProKidney will post -0.49 earnings per share for the current year.

ProKidney Company Profile

(Get Free Report)

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.

Read More

Analyst Recommendations for ProKidney (NASDAQ:PROK)

Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.